2016 · J. Pharmaceutical and Biomedical Analysis · paywalled
Enderle, Foerster & Burhenne
A review of clinical DBS across TDM, metabolic monitoring and trials, arguing that analytical and clinical validation must be obligatory before clinical use.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
2022
This review outlines practical considerations for using dried blood spot microsampling in therapeutic drug monitoring, including patient selection, sampling technique, transport and laboratory analysis, to support its adoption in clinical practice and reduce the need for hospital-based venous sampling.
Best Practices to Implement Dried Blood Spot Sampling for Therapeutic Drug Monitoring in Clinical Practice — Francke et al., Therapeutic drug monitoring · source ↗
2019
The consensus guideline defining the analytical- and clinical-validation requirements for dried-blood TDM: the standardisation reference for implementing a dried assay clinically.
Official IATDMCT Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring — Capiau et al., Therapeutic Drug Monitoring (paywalled) · source ↗
2026
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Clinical Validation of Venetoclax Volumetric Microsampling in Leukemia, with Whole-Blood-to-Plasma Conversion and Self-Microsampling Feasibility — Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
2026
Guidance on capillary-to-plasma conversion: method- and analyte-specific clinical validation with paired capillary–venous samples before reporting plasma-equivalent results.
To Convert or Not to Convert? Official IATDMCT Guideline on Converting Capillary-Blood Microsampling Concentrations to Plasma Concentrations — Boffel et al., Therapeutic Drug Monitoring (paywalled) · source ↗
2026
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
A Review of Blood-Based Microsampling Devices for Patient-Centered Application in Therapeutic Drug Monitoring — Huhn & Scherf-Clavel, Therapeutic drug monitoring (paywalled) · source ↗